| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1950-01-17 |
| Identifiers | MRN HR-EN004-SYN; SSN (made up) 000-04-3318 |
| Document date | 2026-11-01 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urine. Concerns: Painful, interrupted urination and blood in the urine after car journeys; Gout flares keep confining him to his chair, and he does not want to give up wine and good dinners entirely. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2019-05-06 to 2026-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-03-30 | completed | S |
| Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily | Two tablets by mouth daily | Oral route | 2026-03-30 to 2026-05-18 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-18 | active | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-03-02 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery | One capsule by mouth at bedtime | Oral route | 2026-03-30 to 2026-04-20 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-30 | active | S |
| Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2026-05-18 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 days | Two tablets by mouth each morning for 5 days, with food | Oral route | 2026-07-06 to 2026-07-10 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Non-contrast low-dose CT of the abdomen and pelvis: single 2.6 cm bladder stone of about 420 Hounsfield units, suggesting uric acid; no kidney or ureteric stones; no hydronephrosis; enlarged prostate | 2026-03-02 to 2026-03-02 | completed | S |
| 12-lead electrocardiogram: sinus rhythm, no left ventricular hypertrophy | 2026-03-02 to 2026-03-02 | completed | S |
| Uroflowmetry: maximum flow 8.5 mL/s with a voided volume of 210 mL | 2026-03-30 to 2026-03-30 | completed | S |
| Bladder ultrasound for post-void residual: 160 mL | 2026-03-30 to 2026-03-30 | completed | S |
| Office flexible cystoscopy: single large bladder stone, trabeculated bladder, obstructing enlarged prostate with a median lobe, no bladder tumor | 2026-03-30 to 2026-03-30 | completed | S |
| Transurethral laser cystolitholapaxy; stone analysis 100 percent uric acid | 2026-04-20 to 2026-04-20 | completed | S |
| Transurethral resection of the prostate at the same operation; pathology benign prostatic hyperplasia | 2026-04-20 to 2026-04-20 | completed | S |
| Arthrocentesis of the left knee: 25 mL of cloudy yellow fluid; needle-shaped, negatively birefringent crystals; Gram stain negative; culture later showed no growth | 2026-07-06 to 2026-07-06 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-08 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2023-11-06 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2022-04-11 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 2018-09-17 | Tdap vaccine | completed | S |
| 2026-10-19 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-19 | Respiratory syncytial virus vaccine, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1724 | Occupational exposure to heated type metal as a compositor in London, with an obscure pain in the bones of the hand; he stopped heating the type | D (CLM-0002) |
| February 1727 (1726/7 Old Style) | Pleurisy that very nearly carried him off | D (CLM-0010) |
| 1735 | Severe pleurisy ending in an abscess of the left lung, with full recovery | D (CLM-0011) |
| October 22, 1780 | Gout attack at midnight, recorded in his Dialogue between Franklin and the Gout | D (CLM-0005) |
| Winter of 1780 to 1781 | Long and severe fit of gout through the winter, leaving him weakened | D (CLM-0006) |
| About 1781 | First symptoms of the calculous complaint (bladder stone) | D (CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died in 1744 at 89; no illness before his last; cause not recorded in the cited source | 89 | D (CLM-0012) |
| mother | Died in 1752 at 85; no illness before her last; cause not recorded in the cited source | 85 | D (CLM-0012) |
| natural son | Died in 1736 at four of smallpox | 4 | D (CLM-0013) |
| Concern | Status | Evidence |
|---|---|---|
| Painful, interrupted urination and blood in the urine after car journeys | active | S |
| Gout flares keep confining him to his chair, and he does not want to give up wine and good dinners entirely | active | S |
Most recent measures: Urate [Mass/volume] in Serum or Plasma 5.9 on 2026-07-06; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-09-14; Potassium [Moles/volume] in Serum or Plasma 4.7 on 2026-07-06; Carbon dioxide, total [Moles/volume] in Serum or Plasma 26 on 2026-09-14; Urea nitrogen [Mass/volume] in Serum or Plasma 21 on 2026-09-14; Creatinine [Mass/volume] in Serum or Plasma 1.33 on 2026-07-06; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 on 2026-07-06; Glucose [Mass/volume] in Serum or Plasma 104 on 2026-07-06; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-03-02; Phosphate [Mass/volume] in Serum or Plasma 3.4 on 2026-03-02; Parathyrin.intact [Mass/volume] in Serum or Plasma 52 on 2026-03-02; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-03-02; Hemoglobin [Mass/volume] in Blood 14.2 on 2026-03-02; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-03-02; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-03-02; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-03-02; Albumin/Creatinine [Mass Ratio] in Urine 18 on 2026-03-02; pH of Urine 6.3 on 2026-09-14; Erythrocytes [#/area] in Urine sediment by Microscopy high power field 1 on 2026-05-18; Lead [Mass/volume] in Blood 3.1 on 2026-03-02; International Prostate Symptom Score [IPSS] 5 on 2026-09-14; Kidney failure 2-year risk [Likelihood] by KFRE 0.2 on 2026-03-02; Kidney failure 5-year risk [Likelihood] by KFRE 0.6 on 2026-03-02; US Urinary bladder Volume post void 30 on 2026-09-14; Maximum Urine flow by Uroflowmetry 8.5 on 2026-03-30; Volume of 24 hour Urine 1.45 on 2026-05-18; Urate [Mass/time] in 24 hour Urine 840 on 2026-05-18; Citrate [Mass/time] in 24 hour Urine 410 on 2026-05-18; Calcium [Mass/time] in 24 hour Urine 180 on 2026-05-18; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-19; Total score [Mini-Cog] 5 on 2026-10-19; Total score [AUDIT-C] 4 on 2026-10-19 [S]
Strengths and supports: Supports: family nearby, a wide circle of friends and correspondents, and a regular chess partner [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |
| Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection | active | confirmed | N40.1 | S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented. |
| Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolved | resolved | confirmed | M10.062 | S — Synthetic flare at an unscheduled visit; flares are common in the first months of urate-lowering therapy. It does not echo a dated historical attack. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-02 | Urate [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-03-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.36 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 54 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-03-02 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-02 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-03-02 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 52 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-03-02 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-02 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-03-02 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 2026-03-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | <=5.6% | Normal | S |
| 2026-03-02 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 2026-03-02 | pH of Urine | 5.2 | [pH] | 4.5-8 [pH] | Normal | S |
| 2026-03-02 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 12 | /[HPF] | <=2 /[HPF] | High | S |
| 2026-03-02 | Lead [Mass/volume] in Blood | 3.1 | ug/dL | <=3.5 ug/dL | Normal | S |
| 2026-03-02 | International Prostate Symptom Score [IPSS] | 16 | {score} | S | ||
| 2026-03-02 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.2 | % | S | ||
| 2026-03-02 | Kidney failure 5-year risk [Likelihood] by KFRE | 0.6 | % | S | ||
| 2026-03-30 | Urate [Mass/volume] in Serum or Plasma | 7.6 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-03-30 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-30 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-30 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-30 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.34 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 55 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-03-30 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-30 | US Urinary bladder Volume post void | 160 | mL | <=100 mL | High | S |
| 2026-03-30 | Maximum Urine flow by Uroflowmetry | 8.5 | mL/s | >=10 mL/s | Low | S |
| 2026-03-30 | International Prostate Symptom Score [IPSS] | 16 | {score} | S | ||
| 2026-05-18 | Urate [Mass/volume] in Serum or Plasma | 6.4 | mg/dL | 3.5-7.2 mg/dL | Normal | S |
| 2026-05-18 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-18 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-18 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-05-18 | Urea nitrogen [Mass/volume] in Serum or Plasma | 20 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 56 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-05-18 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-18 | pH of Urine | 5.3 | [pH] | 4.5-8 [pH] | Normal | S |
| 2026-05-18 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 1 | /[HPF] | <=2 /[HPF] | Normal | S |
| 2026-05-18 | Volume of 24 hour Urine | 1.45 | L/(24.h) | At least 2.5 L a day for stone prevention | Low | S |
| 2026-05-18 | Urate [Mass/time] in 24 hour Urine | 840 | mg/(24.h) | <=800 mg/(24.h) | High | S |
| 2026-05-18 | Citrate [Mass/time] in 24 hour Urine | 410 | mg/(24.h) | >=320 mg/(24.h) | Normal | S |
| 2026-05-18 | Calcium [Mass/time] in 24 hour Urine | 180 | mg/(24.h) | <=250 mg/(24.h) | Normal | S |
| 2026-05-18 | US Urinary bladder Volume post void | 35 | mL | <=100 mL | Normal | S |
| 2026-05-18 | International Prostate Symptom Score [IPSS] | 6 | {score} | S | ||
| 2026-09-14 | Urate [Mass/volume] in Serum or Plasma | 5.4 | mg/dL | 3.5-7.2 mg/dL | Normal | S |
| 2026-09-14 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-14 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 26 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-09-14 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.32 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 56 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-09-14 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-14 | pH of Urine | 6.3 | [pH] | 4.5-8 [pH] | Normal | S |
| 2026-09-14 | US Urinary bladder Volume post void | 30 | mL | <=100 mL | Normal | S |
| 2026-09-14 | International Prostate Symptom Score [IPSS] | 5 | {score} | S | ||
| 2026-07-06 | Urate [Mass/volume] in Serum or Plasma | 5.9 | mg/dL | 3.5-7.2 mg/dL | Normal | S |
| 2026-07-06 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-06 | Creatinine [Mass/volume] in Serum or Plasma | 1.33 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 55 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-07-06 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-19 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-19 | Total score [AUDIT-C] | 4 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-02 | Body height | 175 | cm | S |
| 2026-03-02 | Body weight | 96 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 74 | /min | S |
| 2026-03-02 | Respiratory rate | 16 | /min | S |
| 2026-03-02 | Body temperature | 36.7 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-30 | Body height | 175 | cm | S |
| 2026-03-30 | Body weight | 95.4 | kg | S |
| 2026-03-30 | Body mass index (BMI) [Ratio] | 31.2 | kg/m2 | S |
| 2026-03-30 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-03-30 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-30 | Heart rate | 70 | /min | S |
| 2026-03-30 | Respiratory rate | 16 | /min | S |
| 2026-03-30 | Body temperature | 36.6 | Cel | S |
| 2026-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-05-18 | Body height | 175 | cm | S |
| 2026-05-18 | Body weight | 94.6 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 30.9 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 72 | /min | S |
| 2026-05-18 | Respiratory rate | 16 | /min | S |
| 2026-05-18 | Body temperature | 36.7 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-14 | Body height | 175 | cm | S |
| 2026-09-14 | Body weight | 93.2 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 30.4 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 68 | /min | S |
| 2026-09-14 | Respiratory rate | 14 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-06 | Body height | 175 | cm | S |
| 2026-07-06 | Body weight | 94 | kg | S |
| 2026-07-06 | Body mass index (BMI) [Ratio] | 30.7 | kg/m2 | S |
| 2026-07-06 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-07-06 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-06 | Heart rate | 84 | /min | S |
| 2026-07-06 | Respiratory rate | 16 | /min | S |
| 2026-07-06 | Body temperature | 37.7 | Cel | S |
| 2026-07-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-19 | Body height | 175 | cm | S |
| 2026-10-19 | Body weight | 93 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 30.4 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 66 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-02 | Primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urine | finished | S |
| 2026-03-30 | Four-week gout and blood pressure review, with urology consultation for a bladder stone | finished | S |
| 2026-05-18 | Review four weeks after stone removal and prostate resection, with urate titration and stone metabolic evaluation | finished | S |
| 2026-09-14 | Gout, stone prevention, kidney, and blood pressure review at about six months | finished | S |
| 2026-07-06 | Same-day sick visit for a hot, swollen left knee | finished | S |
| 2026-10-19 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Start allopurinol 100 mg daily and raise it by 100 mg every 2 to 5 weeks until serum urate is below 6 mg/dL; HLA-B*58:01 testing is not indicated, because he is not of Southeast Asian or African ancestry | completed | GL-ACR-GOUT-2020 | S |
| Colchicine 0.6 mg daily for three to six months as flare prophylaxis; treat flares with a short prednisone course or extra colchicine, and avoid NSAIDs because of chronic kidney disease | completed | GL-ACR-GOUT-2020, GL-CMID-2026 | S |
| Replace hydrochlorothiazide with losartan, which lowers blood pressure and slightly lowers urate; check potassium and creatinine 2 to 4 weeks after starting | completed | GL-ACR-GOUT-2020, GL-CMID-2026, GL-ACC-HTN-2017 | S |
| Urology referral to confirm and remove the bladder stone, look for bladder outlet obstruction and other causes of hematuria, and advise on stone prevention | completed | GL-AUA-STONE, GL-EAU-UROLITH, GL-AUA-BPH | S |
| Uric acid stone prevention: fluids for a urine output of at least 2.5 L a day, potassium citrate to a urine pH of 6.0 to 6.5, stone analysis, and a 24-hour urine collection | completed | GL-AUA-STONE, GL-EAU-UROLITH | S |
| CMID kidney and blood pressure monitoring: blood pressure every visit; eGFR and urine albumin yearly at G3a A1; calcium, phosphate, and PTH at baseline; hemoglobin and the kidney failure risk equation yearly; statin for age over 50 with eGFR below 60; medication review for NSAIDs every visit | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| Limit alcohol, especially beer and spirits, and purine-rich meat, organ meat, and shellfish; avoid sugar-sweetened drinks; aim for gradual weight loss and daily walking | completed | GL-ACR-GOUT-2020 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Serum urate below 6 mg/dL on allopurinol by the six-month review | 2026-09-14 | completed | Serum urate 5.4 mg/dL on allopurinol 300 mg | S |
| Bladder stone removed and comfortable voiding with a normal post-void residual | 2026-05-18 | completed | Stone removed; IPSS from 16 to 6; residual 35 mL | S |
| No gout flare for six months after starting urate-lowering therapy | 2026-09-14 | active | Not met: one knee flare in July while urate was still above target; none since | S |
| Blood pressure below 130/80 without dizziness | 2026-09-14 | completed | 128/76 mmHg on losartan | S |
| Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.5 | 2026-09-14 | active | Urine pH 6.3 on potassium citrate; home measuring jug shows about 2.3 L a day | S |